Effect of periodontitis treatment on histone deacetylase expression levels : a prospective clinical study.

Not Applicable

Active, not recruiting

• Conditions: Gingivitis; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Oral and Gastrointestinal - Normal oral and gastrointestinal development and function; Periodontitis

• Registration Number: ACTRN12621000244808
• Lead Sponsor: niversity of Queensland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-03-08
• Last Update Posted: 21 February 2022

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients 35 years of age or older.

For the periodontal health group:
No history of Stage III and IV periodontitis. BOP<10% and PPD<=3mm

For the gingivitis group*:
>=30% BOP and PPD<=3mm

For the periodontitis group*:
Generalised Stage III and IV Periodontitis, defined by:
>=30% sites with interdental CAL of at least 1-2mm and radiographic bone loss.
Interdental CAL >=5mm
Radiographic bone loss extending to middle third of root and beyond
Tooth loss due to periodontitis
Probing depths >=6mm
Class II or III furcation involvement

*Based on Chapple et al 2018

Exclusion Criteria

Current smokers
Uncontrolled diabetes (HbA1c>=6.5)*
Long-term use of immunosuppressive or anti-inflammatory drugs, periodontal treatment or antibiotics therapy six months prior to investigation
*Based on American Diabetes Association 2018

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evels of histone deacetylase (HDAC) mRNA expression in saliva and GCF, measured using qPCR[0 mo pre-periodontal therapy, and 3 and 6 mo post-periodontal therapy]

Secondary Outcome Measures

Name	Time	Method
Change in probing pocket depth (PPD), measured using a calibrated periodontal probe (Florida Probe).[0 mo pre-periodontal therapy, and 3 and 6 mo post-periodontal therapy];Change in clinical attachment level (CAL), measured using a calibrated periodontal probe (Florida Probe).[0 mo pre-periodontal therapy, and 3 and 6 mo post-periodontal therapy];Change in bleeding on probing (BOP), measured using a calibrated periodontal probe (Florida Probe).[0 mo pre-periodontal therapy, and 3 and 6 mo post-periodontal therapy];Change in plaque index (PI), measured using a calibrated periodontal probe (Florida Probe).[0 mo pre-periodontal therapy, and 3 and 6 mo post-periodontal therapy];Change in no. of residual sites with PPD >=5mm), measured using a calibrated periodontal probe (Florida Probe).[0 mo pre-periodontal therapy, and 3 and 6 mo post-periodontal therapy]